A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
about
An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerationsIn Vitro and In Vivo Models for the Study of Human Polyomavirus InfectionIs there a (host) genetic predisposition to progressive multifocal leukoencephalopathy?Antibody biomarkers in CNS demyelinating diseases - a long and winding roadUse of natalizumab in multiple sclerosis: current perspectives.Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy.Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial.Viral miRNAs in plasma and urine divulge JC polyomavirus infection.Antibodies reacting with JCPyV_VP2 _167-15mer as a novel serological marker for JC polyomavirus infection.JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein levelAnti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.Immunological Markers for PML Prediction in MS Patients Treated with NatalizumabNatalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring.JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.CD4 cell response to interval therapy with natalizumab.Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study.Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathyPrevalence of Anti-JC Virus Antibody in Multiple Sclerosis Patients in Kuwait.Circulating human microRNAs are not linked to JC polyomavirus serology or urinary viral load in healthy subjects.Progressive multifocal leukoencephalopathy in multiple sclerosis.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Natalizumab: risk stratification of individual patients with multiple sclerosis.Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.Progressive multifocal leukoencephalopathy: Dot-shaped inclusions and virus-host interactions.Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS).Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children.Natalizumab in relapsing-remitting multiple sclerosis.Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologics.Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.High cumulative JC virus seroconversion rate during long-term use of natalizumab.Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biologicaJohn Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.
P2860
Q27009769-DAC066B6-A481-4D38-8F6D-D8465706C97FQ28074684-8932536F-C0E3-47D0-B03C-2000E40E81FEQ28084300-847AE387-0A43-48D3-A76D-187D6DAB647AQ28262403-E970C525-7B48-4A3F-855E-A752BC003080Q31114633-72970261-8455-4E97-8B4D-3D3BCC8529CDQ33573208-80FF1BBD-7212-4CEA-8442-69F3A934CF1FQ33693085-530305E2-8BA4-4364-9664-6A06D691A54CQ33736198-B1B64F64-743A-401A-82FB-FBB7FFB6C31BQ34208184-3DAD1748-FA43-4319-A3CB-29C0ED359434Q34325718-932356AA-8227-46CD-911C-890F9A40C8DAQ34351212-2CA85292-4B13-4446-82F7-A58FF3C75E1FQ34803324-A415D96F-3CA0-4CF6-A484-C561C7243588Q34818048-44B5FFC2-14E0-435A-8A22-634CD4C9BE2AQ35093103-5A2CE0F0-AFF3-4F1E-85B2-408B1E0212F8Q35586120-FE7C18BC-0844-4A2D-B793-B650F113E416Q35619220-81BF5986-20B7-4EEA-8834-324CAB9DE4EAQ36314901-C166E2BA-DA6A-4733-81D5-8689D036F495Q36697972-8BD3A91C-BE97-45B4-A31A-C2BEFE86EE15Q36942417-335E1D87-BDE9-4DC3-8F0D-BADB654DF765Q37576809-D001C535-7BE9-40A8-8E2B-1C52D18E90B0Q37621983-0A5EB352-6F47-4679-ACC7-9169C888C940Q38153637-CDBD2AFC-2C18-44E3-829F-5A8A7DDEA6F8Q38172961-25B34ED9-B5EF-46F7-B039-708ADDB6242CQ38221343-DD417303-6556-4461-A72B-6A884780649EQ38261176-6049927A-5A19-4618-9D4E-425501BAAFCBQ38268951-FE0C7D9B-6F36-49FA-91E8-88C416079C44Q38462168-ED627B85-855A-4615-BC0A-3AA2C44F145BQ38577593-2FA92803-5FCA-4A1C-A76B-635B73A6CBF0Q38591114-13533F6C-DF8F-42FC-9923-A1D0D1BCDF84Q38612977-3E8F5050-E7CA-41F4-A65F-2B50C4E0B2F3Q38619288-3B6A88C3-ED0C-46A8-A48D-989FA99ACC2BQ38786252-D38EE19E-B052-4DBF-998A-DD3312C7431DQ38868240-B343BDEC-AF3C-40B9-8E41-179CFD962BF7Q39039495-5B2B1E98-C95F-4392-916F-EBE226548CF5Q39046213-722D16E5-A147-45CD-89BA-26A9B539B401Q39886328-21D2039C-D92A-4FF3-AE17-7C123FC08CFEQ40039520-57EBD8D5-F06F-422F-B2E8-3ED9042D7039Q40061894-E64C2592-CC2C-468B-9F7F-C6C734D02D92Q40067748-64341F21-85AA-4BD1-A0A6-4409D4E89EFEQ40122994-0C5A6214-6E75-48C9-BAE9-957DFEB00256
P2860
A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A second-generation ELISA (STR ...... halopathy risk stratification.
@en
A second-generation ELISA
@nl
type
label
A second-generation ELISA (STR ...... halopathy risk stratification.
@en
A second-generation ELISA
@nl
prefLabel
A second-generation ELISA (STR ...... halopathy risk stratification.
@en
A second-generation ELISA
@nl
P2093
P1476
A second-generation ELISA (STR ...... halopathy risk stratification.
@en
P2093
Albert Castro
Brian Schlain
Dipeshkumar Jaiswal
Meena Subramanyam
Melissa Berman
Suzanne Rivas
Tatiana Plavina
P304
P356
10.1016/J.JCV.2013.02.002
P577
2013-03-05T00:00:00Z